7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Cadrenal Therapeutics
(NASDAQ:CVKD) 

CVKD stock logo

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fib...

Founded: 2022
IPO Price: $5 (Jan 20, 2023)
Full Time Employees: 1
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Cadrenal Therapeutics Days Payable Outstanding ttm (DPO)
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 04.48.8113.2117.6222.0226.4230.83Thousand
Cadrenal Therapeutics Op Cashflow Per Share ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.27-0.23-0.19-0.15-0.12-0.08-0.040
Cadrenal Therapeutics Free Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.27-0.23-0.19-0.16-0.12-0.08-0.040
Cadrenal Therapeutics Cash Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.090.180.280.370.460.550.65
Cadrenal Therapeutics (GAAP) P/E ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.23-2.77-2.3-1.84-1.38-0.92-0.460
Cadrenal Therapeutics P/B ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.470.941.411.882.352.823.29
No extra charts and metrics for this ticker.